scholarly journals p53 in chronic myelogenous leukemia in acute phase.

1991 ◽  
Vol 88 (14) ◽  
pp. 6293-6297 ◽  
Author(s):  
E. Feinstein ◽  
G. Cimino ◽  
R. P. Gale ◽  
G. Alimena ◽  
R. Berthier ◽  
...  

1979 ◽  
Vol 6 (2) ◽  
pp. 155-161 ◽  
Author(s):  
Ronald Stern ◽  
Julie Sorenson ◽  
Doris H. Wurster-Hill ◽  
Gibbons G. Cornwell ◽  
O. Ross McIntyre


Blood ◽  
1989 ◽  
Vol 74 (4) ◽  
pp. 1381-1387 ◽  
Author(s):  
K Kuriyama ◽  
RP Gale ◽  
M Tomonaga ◽  
S Ikeda ◽  
E Yao ◽  
...  

Abstract Most data suggest that malignant transformation in chronic myelogenous leukemia (CML) occurs in hematopoietic stem cell that is the progenitor of myelopoiesis and of B but not T lymphopoiesis. We established a T- lymphoid cell line (CML-T1) from a person with Ph-chromosome-negative CML in acute phase. Evidence of its T-lymphocyte origin includes the pattern cytochemical reactivity, reactivity with anti-T-cell monoclonal antibodies (MoAbs), and rearrangement of the beta-T-cell receptor (TCRB) gene. CML-T1 cells have features of type IV thymocytes. Cytogenetic analyses indicate a 47,XX, del(11), t(6;7)(q23;q24), +mar karyotype. CML-T1 cells exhibit molecular changes typical of CML, including translocation of the ABL protooncogene from chromosome 9 to 22, rearrangement of the BCR gene, and transcription of a chimeric BCR- ABL messenger RNA (mRNA). The ABL insertion on chromosome 22 appears interstitial, similar to other cases of Ph-chromosome-negative CML. These data clearly indicate that T cells can be involved in acute-phase CML. CML-T1 should be useful in studying this process as well as that underlying Ph-chromosome-negative CML.



Author(s):  
N. Niederle ◽  
O. Kloke ◽  
R. Osieka ◽  
D. May ◽  
U. B. Wandl ◽  
...  


Blood ◽  
1989 ◽  
Vol 74 (7) ◽  
pp. 2318-2324 ◽  
Author(s):  
Z Kelman ◽  
M Prokocimer ◽  
S Peller ◽  
Y Kahn ◽  
G Rechavi ◽  
...  

Molecular structural analysis of the p53 gene in patients with Philadelphia chromosome-positive chronic myelogenous leukemia (CML) indicates a significant incidence of gene rearrangements in patients at either accelerated phase or blastic crisis. Southern blot analysis of genomic DNA hybridizing with either genomic or cDNA p53 specific probes indicated that 30% of the CML patients at blastic crisis phase exhibited rearrangements, mostly mapping downstream to the first non- coding exon. This is compatible with the observation that the progression of CML from the chronic to the acute phase involves frequent aberrations in chromosome 17, to which the p53 oncogene has been mapped. Therefore, we suggest that one of the pathways of development of CML to the acute phase is associated with aberrations in the p53 nuclear oncogene.



Blood ◽  
1989 ◽  
Vol 74 (7) ◽  
pp. 2318-2324 ◽  
Author(s):  
Z Kelman ◽  
M Prokocimer ◽  
S Peller ◽  
Y Kahn ◽  
G Rechavi ◽  
...  

Abstract Molecular structural analysis of the p53 gene in patients with Philadelphia chromosome-positive chronic myelogenous leukemia (CML) indicates a significant incidence of gene rearrangements in patients at either accelerated phase or blastic crisis. Southern blot analysis of genomic DNA hybridizing with either genomic or cDNA p53 specific probes indicated that 30% of the CML patients at blastic crisis phase exhibited rearrangements, mostly mapping downstream to the first non- coding exon. This is compatible with the observation that the progression of CML from the chronic to the acute phase involves frequent aberrations in chromosome 17, to which the p53 oncogene has been mapped. Therefore, we suggest that one of the pathways of development of CML to the acute phase is associated with aberrations in the p53 nuclear oncogene.



Blood ◽  
1989 ◽  
Vol 74 (4) ◽  
pp. 1381-1387
Author(s):  
K Kuriyama ◽  
RP Gale ◽  
M Tomonaga ◽  
S Ikeda ◽  
E Yao ◽  
...  

Most data suggest that malignant transformation in chronic myelogenous leukemia (CML) occurs in hematopoietic stem cell that is the progenitor of myelopoiesis and of B but not T lymphopoiesis. We established a T- lymphoid cell line (CML-T1) from a person with Ph-chromosome-negative CML in acute phase. Evidence of its T-lymphocyte origin includes the pattern cytochemical reactivity, reactivity with anti-T-cell monoclonal antibodies (MoAbs), and rearrangement of the beta-T-cell receptor (TCRB) gene. CML-T1 cells have features of type IV thymocytes. Cytogenetic analyses indicate a 47,XX, del(11), t(6;7)(q23;q24), +mar karyotype. CML-T1 cells exhibit molecular changes typical of CML, including translocation of the ABL protooncogene from chromosome 9 to 22, rearrangement of the BCR gene, and transcription of a chimeric BCR- ABL messenger RNA (mRNA). The ABL insertion on chromosome 22 appears interstitial, similar to other cases of Ph-chromosome-negative CML. These data clearly indicate that T cells can be involved in acute-phase CML. CML-T1 should be useful in studying this process as well as that underlying Ph-chromosome-negative CML.



Cancer ◽  
1983 ◽  
Vol 52 (5) ◽  
pp. 841-845 ◽  
Author(s):  
G. Tricot ◽  
M. A. Boogaerts ◽  
A. Broeckaert-Van Orshoven ◽  
A. Criel ◽  
A. Van Hoof ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document